BR112020004101A2 - compostos de espirociclo e métodos para produzir e usar os mesmos - Google Patents

compostos de espirociclo e métodos para produzir e usar os mesmos Download PDF

Info

Publication number
BR112020004101A2
BR112020004101A2 BR112020004101-7A BR112020004101A BR112020004101A2 BR 112020004101 A2 BR112020004101 A2 BR 112020004101A2 BR 112020004101 A BR112020004101 A BR 112020004101A BR 112020004101 A2 BR112020004101 A2 BR 112020004101A2
Authority
BR
Brazil
Prior art keywords
compound
solvate
tautomer
hydrate
stereoisomer
Prior art date
Application number
BR112020004101-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Cheryl A Grice
Olivia D. WEBER
Daniel J. Buzard
Michael B. SHAGHAFI
Todd K. Jones
Original Assignee
Lundbeck La Jolla Research Center, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck La Jolla Research Center, Inc. filed Critical Lundbeck La Jolla Research Center, Inc.
Publication of BR112020004101A2 publication Critical patent/BR112020004101A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BR112020004101-7A 2017-08-29 2018-08-28 compostos de espirociclo e métodos para produzir e usar os mesmos BR112020004101A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762551721P 2017-08-29 2017-08-29
US62/551,721 2017-08-29
PCT/US2018/048372 WO2019046318A1 (en) 2017-08-29 2018-08-28 SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Publications (1)

Publication Number Publication Date
BR112020004101A2 true BR112020004101A2 (pt) 2020-09-24

Family

ID=65527860

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020004101-7A BR112020004101A2 (pt) 2017-08-29 2018-08-28 compostos de espirociclo e métodos para produzir e usar os mesmos

Country Status (27)

Country Link
US (1) US11142526B2 (enExample)
EP (1) EP3675847B1 (enExample)
JP (1) JP7257387B2 (enExample)
KR (1) KR20200046061A (enExample)
CN (1) CN111050765B (enExample)
AU (1) AU2018323459A1 (enExample)
BR (1) BR112020004101A2 (enExample)
CA (1) CA3072923A1 (enExample)
CL (1) CL2020000462A1 (enExample)
CO (1) CO2020001724A2 (enExample)
CR (1) CR20200089A (enExample)
DO (1) DOP2020000039A (enExample)
EA (1) EA202090312A1 (enExample)
EC (1) ECSP20013337A (enExample)
ES (1) ES2952332T3 (enExample)
GE (2) GEP20217327B (enExample)
IL (1) IL272580B (enExample)
JO (1) JOP20200023A1 (enExample)
MA (1) MA50041A (enExample)
MX (1) MX2020002251A (enExample)
NI (1) NI202000014A (enExample)
PE (1) PE20200664A1 (enExample)
PH (1) PH12020500372A1 (enExample)
SG (1) SG11202001022TA (enExample)
UA (1) UA126685C2 (enExample)
WO (1) WO2019046318A1 (enExample)
ZA (1) ZA202001208B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2800565T1 (sl) 2012-01-06 2020-10-30 Lundbeck La Jolla Research Center, Inc. Karbamatne spojine in metode izdelave in uporabe le-teh
EP3455226B1 (en) 2016-05-12 2020-12-30 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
PE20200664A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
BR112020003946A2 (pt) 2017-08-29 2020-09-08 Lundbeck La Jolla Research Center, Inc. compostos de espirociclo e métodos para produzir e usar os mesmos
KR20220034104A (ko) * 2019-07-09 2022-03-17 에프. 호프만-라 로슈 아게 신규 헤테로고리 화합물
CN116096723A (zh) * 2020-08-26 2023-05-09 豪夫迈·罗氏有限公司 用作magl抑制剂的杂环化合物
UY39516A (es) 2020-11-13 2022-05-31 H Lundbeck As Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión
JP7777891B2 (ja) 2021-12-29 2025-12-01 サイ セラピューティクス インコーポレイテッド モノアシルグリセロールリパーゼ(magl)の阻害
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440803A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
WO2009111550A1 (en) 2008-03-05 2009-09-11 Targacept, Inc. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
CN102575076B (zh) 2009-09-29 2014-08-20 普立万公司 具有模拟金属或珠光外观的聚酯制品
CA2778484C (en) 2009-10-23 2018-07-31 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US9108937B2 (en) 2010-03-04 2015-08-18 Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
SI2800565T1 (sl) 2012-01-06 2020-10-30 Lundbeck La Jolla Research Center, Inc. Karbamatne spojine in metode izdelave in uporabe le-teh
DK2900669T3 (da) 2012-09-25 2019-11-04 Hoffmann La Roche Hexahydropyrrolo[3,4-C]pyrrolderivater og relaterede forbindelser som autotaxin (ATX)-inhibitorer og som inhibitorer af lysophosphatidsyre (LPA)-produktion til behandling af f.eks. nyresygdomme
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター,インク. ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
US10093630B2 (en) * 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
EP3271352B1 (en) 2015-03-18 2021-05-12 H. Lundbeck A/S Piperazine carbamates and methods of making and using same
EA035823B1 (ru) 2015-07-31 2020-08-17 Пфайзер Инк. 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl
WO2017087858A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
TWI738753B (zh) 2016-03-31 2021-09-11 日商武田藥品工業股份有限公司 雜環化合物
EP3455226B1 (en) 2016-05-12 2020-12-30 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190050A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
AU2017361254B2 (en) 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
KR102508739B1 (ko) 2016-11-16 2023-03-09 하. 룬드벡 아크티에셀스카브 Magl 억제제의 결정형
PE20200664A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
BR112020003946A2 (pt) 2017-08-29 2020-09-08 Lundbeck La Jolla Research Center, Inc. compostos de espirociclo e métodos para produzir e usar os mesmos

Also Published As

Publication number Publication date
EP3675847A4 (en) 2021-01-06
US20200255427A1 (en) 2020-08-13
MA50041A (fr) 2020-07-08
EP3675847A1 (en) 2020-07-08
CO2020001724A2 (es) 2020-02-28
EP3675847B1 (en) 2023-07-12
SG11202001022TA (en) 2020-03-30
GEP20217327B (en) 2021-12-10
EA202090312A1 (ru) 2020-08-05
AU2018323459A1 (en) 2020-02-20
MX2020002251A (es) 2020-07-20
NI202000014A (es) 2020-07-28
KR20200046061A (ko) 2020-05-06
ECSP20013337A (es) 2020-04-22
CR20200089A (es) 2020-04-08
JP7257387B2 (ja) 2023-04-13
DOP2020000039A (es) 2020-08-31
RU2020107163A (ru) 2021-09-30
CL2020000462A1 (es) 2020-07-10
US11142526B2 (en) 2021-10-12
IL272580A (en) 2020-03-31
EP3675847C0 (en) 2023-07-12
CN111050765A (zh) 2020-04-21
JP2020532545A (ja) 2020-11-12
GEAP202115281A (en) 2021-08-10
CN111050765B (zh) 2024-01-02
UA126685C2 (uk) 2023-01-11
PH12020500372A1 (en) 2020-12-07
RU2020107163A3 (enExample) 2022-03-15
WO2019046318A1 (en) 2019-03-07
PE20200664A1 (es) 2020-06-11
ES2952332T3 (es) 2023-10-30
CA3072923A1 (en) 2019-03-07
ZA202001208B (en) 2021-08-25
JOP20200023A1 (ar) 2020-02-02
IL272580B (en) 2022-09-01

Similar Documents

Publication Publication Date Title
BR112020004101A2 (pt) compostos de espirociclo e métodos para produzir e usar os mesmos
CA2719876C (en) Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
BR112020003946A2 (pt) compostos de espirociclo e métodos para produzir e usar os mesmos
RU2679914C9 (ru) Конденсированные трициклические производные имидазола в качестве модуляторов активности tnf
JP2021193128A (ja) 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物
RU2684641C1 (ru) Производные пиразолопиридина в качестве модуляторов активности tnf
BR112020026534A2 (pt) Compostos de heteroarila para o tratamento da doença de huntington
AU2018271876B2 (en) Pyrazole MAGL inhibitors
JP2019508407A (ja) 化合物、組成物及び方法
BR112019024488A2 (pt) inibidores de pirazol magl
BR112020003725A2 (pt) inibição da peptidase 30 específica de ubiquitina
JP2017516850A (ja) Jak阻害剤である5−クロロ−2−ジフルオロメトキシフェニルピラゾロピリミジン化合物
US20240368091A1 (en) Bicyclic 1,4-diazepanones and therapeutic uses thereof
CA3108076A1 (en) Muscarinic acetylcholine m1 receptor antagonists
TW201321384A (zh) 作為鈣通道阻斷劑之經取代之八氫吡咯并[1,2-a]吡□磺醯胺
JP7473544B2 (ja) アデノシン受容体アンタゴニストとしての5-アザインダゾール誘導体
KR20230015404A (ko) 무스카린성 아세틸콜린 수용체 m5의 경쟁적 억제제 및 비경쟁적 억제제
AU2014257578B2 (en) Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments
TW202440091A (zh) Nampt調節劑
RU2781639C2 (ru) Спироциклические соединения и способы их получения и применения
WO2014051055A1 (ja) キヌクリジンウレア誘導体及びその医薬用途
EA041386B1 (ru) Спироциклические соединения и способы их получения и применения
HK40032869A (en) Spirocycle compounds and methods of making and using same
HK40032869B (en) Spirocycle compounds and methods of making and using same
WO2026012492A1 (en) Heterocyclic compounds as il-17 inhibitors

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: H. LUNDBECK A/S (DK)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2789 DE 18-06-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.